There are 3163 resources available
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13
2014P - Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Presenter: Patrizia Giannatempo
Session: Poster session 13
2015P - Serum nectin-4: Prognostic and predictive value in bladder cancer?
Presenter: Kerstin Junker
Session: Poster session 13
2016P - Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Presenter: Cora Sternberg
Session: Poster session 13
2017P - Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response
Presenter: Jiwon Kim
Session: Poster session 13
2019P - Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe
Presenter: Jose Tapia
Session: Poster session 13
2020TiP - SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations
Presenter: Yohann Loriot
Session: Poster session 13
2022TiP - Stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV)
Presenter: Tian Zhang
Session: Poster session 13